“Prevencio is pleased with the continued development of our patent portfolio. This patent issuance for HART CVE demonstrates the U.S. Patent Office’s recognition of our novel invention for a machine learning-driven, multiple protein, algorithmically scored blood test for detection of adverse cardiac events,” said Rhonda Rhyne, President and Chief Executive Officer of Prevencio.
The company recently announced an international 1,500+ patient study using HART CVE. When the HART CVE test score was divided into low-risk and high-risk categories, the test predicted with 98% accuracy (negative predictive value) that a low-risk patient would not have a heart attack or major cardiac event within one year.
“This AI-powered risk score test provides improved accuracy as compared to clinical risk factors and single protein tests. The test could be particularly useful for patients with suspected or known stable and acute heart disease, for which there are very few prognostic risk models,” said James L. Januzzi, MD, a practicing cardiologist at Massachusetts General Hospital, Professor of Medicine at Harvard Medical School and Principal Investigator in development, validation, and ongoing testing of the HART CVE test. “In addition to leading to more appropriate care of patients, it is well-suited for a role in ‘enriching’ pharmaceutical cardiac clinical trials, which could lead to lower trial costs and reduced time to complete clinical trials.”
Cardiovascular disease is the leading cause of death in the U.S. and globally. According to the American Heart Association (AHA), the U.S. spends approximately $316 billion annually on cardiovascular disease and stroke, or approximately 10% of the $3.2 trillion spent on total healthcare. By 2030, AHA projects that more than 40% of the U.S. adult population will have cardiovascular disease, with healthcare-related expenditures of $1 trillion.
In addition to the HART CVE test for one-year risk of a cardiac event, Prevencio has recently launched a second multi-protein blood test, HART CADhs, for diagnosing obstruction of the heart arteries. HART CADhs was shown to be more accurate (86% AUC accuracy) than standard-of-care stress tests (52% AUC accuracy). HART CVE and HART CADhs tests are currently available to medical professionals for patient use. For additional information, visit Prevencio, Inc.
About Prevencio HART Tests:
Powered by Artificial Intelligence (AI), Prevencio is revolutionizing blood tests for cardiovascular disease and custom diagnostics. Employing this novel approach, the company has developed seven blood tests that significantly improve diagnoses for a variety of heart and blood vessel-related complications.
3 Lead HART Tests:
- HART CVETM – 1-year risk of heart attack, stroke, or cardiac death
- HART CADhsTM – obstructive coronary artery disease (CAD) diagnosis
- HART KDTM – Kawasaki Disease diagnosis
HART test results are peer-reviewed and have been presented/published at 22 leading cardiology meetings/journals.
About Prevencio, Inc.
Prevencio’s value proposition is “Preventing the Preventable” — That is, preventing unnecessary procedures, related side effects, and expense, as well as improving patient outcomes and clinical trials through more accurate blood tests for cardiovascular disease conditions. Prevencio utilizes Machine Learning (Artificial Intelligence) + Multi-Proteomic Biomarkers + Proprietary Algorithms to deliver cardiovascular diagnostic & prognostic tests that are significantly more accurate than standard-of-care stress tests, coronary artery calcium scores, single protein tests, and multi-protein tests. The company is headquartered in Kirkland, Washington. For additional information, visit www.PrevencioMed.com.
Forward-Looking (Safe Harbor) Statement:
Except for historical and factual information contained herein, this press release contains forward-looking statements, such as market need and size, the accuracy of which is necessarily subject to uncertainties and risks including the Company’s sole dependence on HART technology and various uncertainties of development-stage companies. The Company does not undertake to update disclosures contained in this press release.
Christiaan Boer, email@example.com; 406-360-5239
Categories: National Headlines